A Pilot Phase II Study With Brentuximab Vedotin (SGN-035) as Pre-ASCT Induction Therapy in Relapsed/Refractory Hodgkin’s Lymphoma Patients Non Responding to IGEV Salvage Treatment (NCT02244021)
A pilot phase II study with brentuximab vedotin as pre-ASCT (pre-autologous stem cell transplant) induction therapy in relapsed/refractory Hodgkin’s lymphoma patients non-responding to IGEV, a rather recently introduced combination salvage chemotherapy for the treatment of this disease. IGEV combination chemotherapy includes ifosfamide, gemcitabine, vinorelbine and prednisone.
This trial is sponsored by Fondazione Italiana Linfomi ONLUS. 
- Condition: Lymphoma
- Phase: II
- Estimated Enrollment: 13
- Start: September 2014
- Estimated Completion: March 2017
- Last verified: February 2014
Last Editorial review: July 6, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.